A recent study published in the American Medical Association’s journal, JAMA, has found that a class of diabetes medications, including Ozempic, is linked to a reduced risk of certain obesity-related cancers. The research compared patients with Type 2 diabetes who were treated with insulin to those who were given GLP-1 agonists like Ozempic between 2005 and 2018. The findings revealed that patients receiving GLP-1 agonists had a significantly lower risk of developing 10 out of 13 cancers studied, including kidney, pancreatic, esophageal, ovarian, liver, and colorectal cancer.
The study highlighted the association between obesity and cancer, with obesity being linked to at least 13 different types of cancer. The lead author of the study, Rong Xu, mentioned that the results suggest that GLP-1 agonists could potentially break the link between obesity and cancer. Among the drugs studied were semaglutide, sold commercially as Ozempic, as well as liraglutide and others. Ozempic, which was approved in the United States in 2017, is part of a new generation of GLP-1 agonists known for their significant weight loss effects.
GLP-1 agonists have been available for about two decades, but the newer generation of drugs, including Ozempic, has gained popularity for their enhanced weight loss benefits. Xu suggested that the protective benefits observed in the study might lead healthcare providers to consider GLP-1 treatments for diabetes patients instead of alternative medications like insulin. The study did not find a significant change in risk for thyroid cancer or breast cancer in post-menopausal women, but the overall results indicate a positive correlation between GLP-1 agonists and a reduced risk of obesity-related cancers.
In conclusion, the study’s findings support the potential use of GLP-1 agonists like Ozempic in reducing the risk of certain obesity-related cancers in patients with Type 2 diabetes. These medications, known for their weight loss effects, show promise in breaking the link between obesity and cancer. Healthcare providers may consider prescribing GLP-1 treatments as a preventative measure for cancer in addition to managing diabetes. Further research may be needed to explore the long-term effects and mechanisms of action behind the protective benefits observed in this study.
